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BACKGROUND. The presence of myoepithelial cells (MECs) in ﬁne-needle aspira-
tion biopsies (FNAB) of the breast constitute an important criterion used to
diagnose benign breast lesions. However, MECs sometimes have a distorted cyto-
morphology, and most of the previously evaluated myoepithelial markers do not
have satisfactory sensitivity and speciﬁcity. p63, a recently characterized p53
homolog, is a nuclear transcription factor that is expressed in basal cells of
multilayered epithelia and myoepithelial cells of the breast. The authors analyzed
the immunocytochemical distribution of p63 in a series of 82 breast FNABs (30
benign lesions and 52 malignant breast lesions).
METHODS. Eighty-two archival, Papanicolaou-stained smears of breast lesions were
retrieved from the ﬁles of the authors’ institutions. Immunocytochemistry was
performed according to the streptavidin-biotin-peroxidase complex technique us-
ing the antibody 4A4 (against all p63 isoforms). Two pathologists evaluated the
distribution of p63 positive cells. Only nuclear reactivity was considered speciﬁc.
RESULTS. In benign lesions, p63 decorated the nuclei of MECs in all samples. p63
also stained naked nuclei in ﬁbroadenomas. In malignant lesions, p63 was positive
in MECs overlying malignant cell clusters in all 8 samples of ductal carcinoma in
situ (DCIS), in 9 of 16 samples of pure invasive carcinomas (IC), and in 16 of 20
samples that contained both DCIS and IC. In 18 samples (36%), a variable popu-
lation of p63 positive, malignant cells was observed. p63 failed to decorate stromal,
neural, adipocytic, and smooth muscle cells in all samples.
CONCLUSIONS. p63 is a reliable nuclear marker of MECs in breast aspirates. Re-
gardless of the fact that variable proportions of p63 positive, malignant cells were
observed in 36% of breast carcinoma aspirates, p63 may be a useful adjunct
antibody to conﬁrm the presence of MECs in FNABs of benign breast lesions.
Cancer (Cancer Cytopathol) 2003;99:172–9. © 2003 American Cancer Society.
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F ine-needle aspiration biopsy (FNAB) of the breast is a widelyaccepted technique in the diagnosis and management of both
palpable breast lesions and nonpalpable breast lesions due to its
simplicity, accuracy, and utility for the avoidance of more invasive
procedures.1,2 Regardless of the growing popularity of core needle
biopsies of the breast, FNAB remains one of the methods included in
the triple-test approach to breast lesions, in which clinical, mammo-
graphic, and cytologic features are used to tailor the best manage-
ment for a given patient.1–4 Moreover, FNAB specimens may be used
to assess prognostically signiﬁcant pathologic parameters of breast
carcinoma, including nuclear grade, histologic type, ploidy, prolifer-
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ation index, immunocytochemical expression of hor-
mone receptors, c-erb-B2, and p53.3
Breast aspirates usually are comprised of epithe-
lial (secretory) and myoepithelial cells as well as mes-
enchymal cells, including stromal cells, endothelial
cells, pericytes, adipocytes, and neural cells.1,2,4 The
architectural distribution of epithelial, myoepithelial,
and mesenchymal cells as well as cytologic features
should be assessed carefully. In some situations, the
identiﬁcation of myoepithelial cells is of utmost im-
portance, because their presence has been used as a
marker of benign breast lesions.1,5 However, these
cells sometimes have unusual cytomorphologic fea-
tures and may be confused with apoptotic cells, mac-
rophages/histiocytes, and stromal cells.1,2
Several antibodies have been employed as myo-
epithelial markers, including S-100 protein, -smooth
muscle actin, calponin, myosin heavy chain, and
maspin.1,2,4–12 Recently, p63, a p53 homologue, has
been characterized as a reliable marker of myoepithe-
lial cells of breast lobules and ducts.13,14 Most impor-
tantly, p63 is the ﬁrst nuclear marker for myoepithelial
cells.13,14 To the best of our knowledge, only a brief,
preliminary assessment of p63 expression in FNAB of
the breast has been published to date.13 We evaluated
the distribution of p63 in 82 FNABs of the breast as
well as its putative applications in routine cytopathol-
ogy practice.
MATERIALS AND METHODS
FNABs of the breast were retrieved retrospectively
from the cytopathology archives of the Institute of
Molecular Pathology and Immunology, University of
Porto, Porto, Portugal, and the Department of Pathol-
ogy, Hospital Sa˜o Joa˜o, Porto, Portugal. Only Papani-
colaou-stained slides were included in the current
study. Eighty-two samples were collected and re-
viewed by two of the authors: 30 benign breast lesions
and 52 carcinomas (in situ and invasive).
The cytologic samples were reviewed by two of the
authors, and the most representative Papanicolaou-
stained cytology slide was chosen for the immunocy-
tochemical analysis, as described previously.15 Brieﬂy,
the coverslips of Papanicolaou-stained slides were re-
moved. Heat-induced antigen retrieval in a wet bath,
using either the Dako antigen-retrieval solution or
citrate buffer, pH 6.0, was performed for 20 minutes in
all samples. Immunocytochemistry was performed ac-
cording to the streptavidin-biotin-peroxidase tech-
nique using the antibody 4A4 raised against p63 (di-
lution 1:200; Neomarkers, Freemont, CA), as described
elsewhere.16 Only cells that showed strong and dis-
tinctive nuclear immunoreactivity for p63 were con-
sidered positive. Cytoplasmic and membranous stain-
ing was considered nonspeciﬁc. Positive controls
(histologic sections of a sclerosing papilloma with
myoepithelial hyperplasia) and negative controls
(omission of the primary and secondary antibodies)
were included in each slide run. All controls yielded
appropriate results.
Two of the authors independently evaluated the
distribution of p63 in epithelial cells, myoepithelial
cells, stromal tissue fragments, adipocytes, blood ves-
sels, and neoplastic cells. Special attention was paid to
the immunoreactivity of p63 in the so-called naked
nuclei (NN) observed in benign lesions.
RESULTS
Benign Lesions
The benign breast lesions assessed in this study in-
cluded 11 ﬁbroadenomas, 1 papillary lesion, and 6
lesions that were diagnosed hypercellular for patient
age. The latter seven lesions were diagnosed histolog-
ically as one intraductal papilloma (Table 1, Patient
24) and six ﬁbrocystic changes with ductal hyperplasia
and adenosis (Table 1, Patients 25–30). Twelve pa-
tients were diagnosed with benign lesions due to the
absence of clinical, radiologic, or cytologic criteria to
diagnose malignancy (Table 1, Patients 1–12).
All FNABs of benign lesions showed a consistent
distribution of p63 in the nuclei of myoepithelial cells,
which were arranged in three distinctive patterns: 1)
overlying epithelial sheets and clusters (Fig. 1A,B), 2)
on the borders of epithelial sheets, and 3) isolated cells
admixed with epithelial clusters. In all lesions that
were diagnosed as ﬁbroadenomas, bipolar NN consis-
tently were decorated by p63 (Fig. 1C). In contrast,
stromal cells and fat cells lacked p63 in all but one
lesion. There was no immunoreactivity observed in
stromal cells or endothelial cells in ﬁbrovascular cores
from papillary lesions (Fig. 1D). In 17 lesions, no back-
ground staining was observed; in 12 lesions, a faint
background was found but by no means impaired the
evaluation of the cytologic specimens. In one lesion, a
strong background was found that partially impaired
the evaluation of the sample. Table 1 summarizes the
distribution of p63 in benign specimens.
Malignant Lesions
Forty-four histologically conﬁrmed lesions were diag-
nosed either as ductal carcinoma in situ (DCIS) (8
lesions), invasive ductal carcinoma (IDC) of no special
type (28 lesions), or special types of invasive carci-
noma (8 lesions). Eight other lesions had a diagnosis
of malignancy, and the patients were referred for ad-
juvant therapy at another hospital. Tables 1 and 2
summarize the clinical pathologic characteristics of
the benign and malignant lesions evaluated herein.
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There were p63 positive myoepithelial cells overlying
tridimensional, malignant cell clusters observed in all
DCIS specimens (Fig. 2A). In 4 lesions, scattered, p63
positive, bipolar cells with ovoid-to-elongated nuclei
and spindle-shaped cytoplasm also were observed.
Myoepithelial cells overlying malignant cell clus-
ters were observed in 9 of 16 pure invasive carcinoma
(IC) samples (Fig. 2B). However, in these samples, p63
positive myoepithelial cells were much less conspicu-
ous compared with the cells observed in DCIS sam-
ples. In seven samples, scattered myoepithelial cells
admixed with noncohesive, neoplastic cells were
found. In six samples, no myoepithelial cells were
observed.
In IC lesions that were associated with DCIS, p63
positive myoepithelial cells overlying malignant cell
clusters were found in 16 specimens. In 10 specimens,
scattered myoepithelial cells were observed in the
background. It should be noted that, in these speci-
mens, p63 positive cells were as abundant as they
were in DCIS samples.
In no sample did p63 decorate cells with cytomor-
phologic features of stromal cells, adipocytes, endo-
thelial cells, or nerve sheath cells. In 50 samples, no
background staining was found. In two samples, a
strong background that partially impaired evaluation
was observed.
One unexpected ﬁnding was the presence of p63
positive malignant cells in 16 samples (3 of 8 samples
of pure DCIS, 6 of 16 samples of pure IC, and 7 of 20
samples of IC associated with DCIS) (Fig. 2C,D). It
should be emphasized, that in 9 samples, only a mi-
nority of neoplastic cells showed p63 staining (1–5% of
neoplastic cells); in 6 samples, 5–15% of neoplastic
cells showed p63 immunoreactivity; and, in 1 sample,
the majority of the neoplastic cells were decorated by
p63 (it is interesting to note that this patient had a
metaplastic breast carcinoma comprised of high-
TABLE 1
Summary of Clinical Pathologic Features of 30 Patients with Benign Results
Patienta Gender Age (yrs) Cytologic diagnosis P63 overlying P63 naked nuclei p63 Bipolar cells
1 F 49 Benign   
2 F 42 Benign   
3 F 44 Benign  Rare 
4 F 49 Benign   
5 F 47 Benign   
6 M 29 Benign NA NA 
7 F 40 Benign   
8 F 51 Benign   
9 F 51 Benign   
10 F 21 Benign   
11 F 54 Benign   
12 F 52 Benign   
13 F 48 Fibroadenoma   
14 F 26 Fibroadenoma   
15 F 34 Fibroadenoma   
16 F 44 Fibroadenoma   
17 F 25 Fibroadenoma   
18 F 53 Fibroadenoma   
19 F 52 Fibroadenoma   
20 F 29 Fibroadenoma   
21 F 63 Fibroadenoma   
22 F 35 Fibroadenoma   
23 F 20 Fibroadenoma   
24 F 18 Papillary lesion  Rare 
25 F 52 Hypercellular for patient age   
26 F 64 Hypercellular for patient age   
27 F 53 Hypercellular for patient age   
28 F 64 Hypercellular for patient age   
29 F 36 Hypercellular for patient age   
30 F 73 Hypercellular for patient age   
: negative; : positive; P63 overlying: p63 positive myoepithelial cells overlying malignant cell clusters; F: female; M: male; NA: not available.
a Patients 1–12 did not have histologic follow-up.
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grade spindle cells with foci of squamous differentia-
tion) (Table 2, Patient 37).
Eight additional lesions that were diagnosed as
carcinoma (Table 2, Patients 45–52) also were evalu-
ated for p63 distribution. In these lesions, the cyto-
logic criteria for malignancy were fulﬁlled completely.
Two lesions showed p63 positive myoepithelial cells
overlying malignant cell clusters, and two lesions
showed scattered myoepithelial cells admixed with
noncohesive, neoplastic cells. In three lesions, p63
immunoreactivity was observed in the nuclei of ma-
lignant cells (5% of neoplastic cells).
DISCUSSION
In routine cytologic preparations, the precise identiﬁ-
cation of myoepithelial cells plays a major role in the
diagnostic assessment of several types of breast le-
sions. These cells are a constituent of the normal basal
layer of the breast lobules and ducts and usually are
lost during malignant progression.1,2,4–14,17–20 How-
ever, identiﬁcation of myoepithelial cells in breast bi-
opsies and FNAB specimens sometimes is difﬁcult
using Papanicolaou-stained or Giemsa-stained prepa-
rations.1,4,12
Based on their biphenotypic (epithelial and
smooth muscle-like) properties,21 several antibodies
directed against myoepithelial cells have been raised.
These target either smooth muscle-related antigens
(-smooth muscle actin, calponin, h-caldesmon, and
smooth muscle myosin heavy chain)4–6,8–12 or cyto-
keratins that are expressed speciﬁcally by basal/myo-
epithelial cells (cytokeratin 5/6, cytokeratin 14, and
cytokeratins that are recognized by the antibody
34E12).17–20
Currently, several investigations mitigate against
using S-100 protein, because it has a high sensitivity
but a very low speciﬁcity for myoepithelial cells.4,5,11,14
Most of the smooth muscle-related antibodies, such as
-smooth muscle actin, calponin, h-caldesmon, and
smooth muscle myosin heavy chain, lack speciﬁcity
for myoepithelial cells, because they cross react with
breast stromal cells and myoﬁbroblasts4,5,11,14 as well
as with neoplastic cells.11 Basal layer speciﬁc cyto-
keratins have a low sensitivity for myoepithelial
cells,17,19,20 mainly for those located in the lobules,
and also stain a variable proportion of breast carcino-
mas.17–21
The recently characterized p53 homolog, p63, is
expressed consistently in the basal cell population of
several types of stratiﬁed epithelia.13,14,22–24 The p63
gene is located on 3q27 and encodes at least six dif-
ferent isoforms, three with a transactivating (TA) N-
terminal domain and three dominant negative (N)
isoforms that lack the N-terminal TA domain.13,14,22–24
The N-p63 isoforms may participate in an alternative
mechanism to overcome p53-related cell cycle arrest
and apoptosis, thus constituting an efﬁcient mecha-
nism to maintain a basal cell population.13,14,22–24
FIGURE 1. (A) Low-magniﬁcation pho-
tomicrograph showing p63 positive myo-
epithelial cells overlying epithelial clusters.
(B) Medium magniﬁcation showing p63
positive myoepithelial cells overlying an
epithelial cell sheet. (C) p63 Decorated
myoepithelial cells and naked nuclei. (D)
Papillary lesion showing p63 positive myo-
epithelial cells. Note the absence of p63
immunoreactivity in the nuclei of stromal
cells of this papillary lesion (streptavidin-
biotin-peroxidase/diaminobenzidine tetra-
hydrocloride; original magniﬁcation 100
[A],  200 [B, C],  40 [D]).
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1 F 49    DCIS   
2 F 79    DCIS H  
3 F 47    DCIS H  
4 F 65    DCIS H  
5 F 80    DCIS I  
6 F 59    DCIS I  
7 F 63    DCIS L  
8 F 69    DCIS L  
9 F 53    DCIS  IDC H Ductal I
10 F 64    DCIS  IDC H Ductal III
11 F 64    DCIS  IDC H Ductal I
12 F 51    DCIS  IDC H Ductal II
13 F 68    DCIS  IDC H Ductal III
14 F 53    DCIS  IDC H Ductal II
15 F 48    DCIS  IDC H Ductal III
16 F 41    DCIS  IDC H Ductal I
17 F 68    DCIS  IDC H Ductal III
18 F 50    DCIS  IDC H Ductal II
19 F 76    DCIS  IDC I Ductal II
20 F 60    DCIS  IDC I Ductal II
21 F 62    DCIS  IDC I Ductal I
22 M 67    DCIS  IDC I Ductal II
23 F 71    DCIS  IDC I Ductal I
24 F 63    DCIS  IDC I Ductal I
25 F 74    IDC  Ductal II
26 F 55    IDC  Ductal III
27 M 59    IDC  Ductal III
28 F 71    IDC  Ductal I
29 F 67    IDC  Ductal III
30 F 54    IDC  Ductal III
31 F 44    IDC  Ductal II
32 F 63    IDC  Ductal I
33 F 49    IDC  Ductal I
34 F 59    IDC  Ductal I
35 F 51    IDC  Ductal II
36 F 75    IDC  Ductal III
37 F 82    IDC  MBC III
38 F 48    IDC  MC II
39 F 71    IDC  MC II
40 F 68    DCIS  IDC H MC II
41 F 54    DCIS  IDC H MC II
42 F 40    DCIS  IDC H MC III
43 F 80    IDC  Mucinous I
44 F 62    DCIS  IDC H Mucinous I
45 F 69    N.O. N.O. N.O. N.O.
46 F 77    N.O. N.O. N.O. N.O.
47 F 58    N.O. N.O. N.O. N.O.
48 F 49    N.O. N.O. N.O. N.O.
49 F 79    N.O. N.O. N.O. N.O.
50 F 60    N.O. N.O. N.O. N.O.
51 F 47    N.O. N.O. N.O. N.O.
52 F 71    N.O. N.O. N.O. N.O.
DCIS: ductal carcinoma in situ; H: high; I: intermediate; L: low; IDC: invasive ductal carcinoma; F: female; : negative; : positive; MBC: metaplastic breast carcinoma; MC: mixed carcinoma; N.O.: not observed;
P63 overlying: p63 positive myoepithelial cells overlying malignant cell clusters; P63 on the background: p63 positive myoepithelial cells admixed with the neoplastic population; p63 neoplastic cells: p63 positive
neoplastic cells.
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Along with 14 other authors,13,25,26 we have demon-
strated that p63 is expressed consistently in myoepi-
thelial cells of the breast lobules and ducts as well as in
the myoepithelial cells of sweat glands.16
In breast FNAB samples, p63 is expressed selec-
tively by myoepithelial cells, for which it is a very
reliable marker.13 It is interesting to note that the
consistent expression of p63 in NN of benign breast
FNAB samples favors a myoepithelial origin for these
cells.13 NN have been described in ﬁbroadenomas,
Phyllodes tumor, ﬁbrocystic change, pseudoangioma-
tous stromal hyperplasia, sclerosing lobular hyperpla-
sia, benign papillary lesions, papillary adenoma of
the nipple, gynecomastia, and other benign condi-
tions.4,13,27,28 In all of the ﬁbroadenoma lesions ana-
lyzed herein, we observed p63 positive NN admixed
with sheets of epithelial cells. Our results are in accor-
dance with early reports28–30 suggesting that NN have
a myoepithelial origin and with the preliminary results
of Barbareschi and colleagues.13 Their designation
suggests that NN do not have intact cytoplasm. Hence,
we do not expect these nuclei to react with cytoplas-
mic markers of smooth muscle differentiation.4,27 In
the current study and in that of Barbareschi et al.,13
most NN showed evidence of a myoepithelial origin.
The presence of myoepithelial cells overlying ma-
lignant cell clusters has been suggested as a very spe-
ciﬁc indicator of an in situ component.1 Despite its
high prevalence in DCIS samples and DCIS plus IC
samples, p63 positive myoepithelial cells also were
observed in 56.25% of pure IC samples. Thus, based
on our ﬁndings, the presence of p63 positive myoep-
ithelial cells should not be used as a speciﬁc criterion
to rule out the presence of an invasive component.
Another important aspect of p63 immunocyto-
chemistry is that, whereas some markers show strong
background staining or even aberrant nuclear immu-
noreactivity in cytologic samples,9 p63 showed strong
immunoreactivity that was conﬁned to the nuclei of
myoepithelial cells. In only three lesions, the back-
ground was so high that it impaired evaluation of the
cytologic preparation.
Most importantly, the major surprising and inter-
esting ﬁnding of p63 immunoreactivity in cytologic
samples is the presence of p63 positive malignant
cells. In previous studies, Barbareschi et al.13 and
Kaufmann et al.26 reported the presence of a variable
proportion (5–15%) of p63 positive neoplastic cells
in up to 4.6% and 11% of breast carcinomas, respec-
tively. In the current study, we observed rare p63
positive malignant cells (1–5%) in 12 specimens (23%)
and frequent positive cells (5%) in 7 specimens
(13%). It should be noted that, in all but one specimen,
the majority of neoplastic cells were p63 negative, and
a correct diagnosis of malignancy would obviously be
achieved. The sample with diffuse p63 immunoreac-
tivity was a metaplastic carcinoma. It is interesting to
note that we have demonstrated,31 along with oth-
FIGURE 2. (A) Low-magniﬁcation view
of a ductal carcinoma in situ with p63
positive myoepithelial cells overlying ma-
lignant cell clusters. (B) Medium magniﬁ-
cation of an invasive ductal carcinoma
with malignant cells arranged in duct-like
structures and showing p63 positive over-
lying myoepithelial cells. (C) p63 Positive
malignant cells. (Inset) Malignant cells
forming lumen and showing p63 immuno-
reactivity. (D) Histologic section showing
an invasive ductal carcinoma with scat-
tered p63 positive nuclei (streptavidin-bi-
otin-peroxidase/diaminobenzidine tetrahy-
drocloride; original magniﬁcation  100
[A],  200 [B, C],  400 [inset, D]).
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ers,13,32 that p63 is expressed consistently in up to
62.5% of metaplastic breast carcinoma samples, inde-
pendent of their morphologic appearance. In addi-
tion, several lines of evidence support the ﬁnding that
up to 18% of high-grade, invasive ductal carcinomas of
the breast show myoepithelial-like or basal-like differ-
entiation.21,33,34 Thus, one possible explanation for the
expression of p63 in malignant cells may reﬂect an
aberrant or partial myoepithelial-like or basal-like dif-
ferentiation.13,14,21,33
In conclusion, the current study demonstrated
that 1) p63 is a reliable nuclear marker of myoepithe-
lial cells in the breast and may be used to distinguish
these cells from their mimics in FNABs; 2) benign
lesions usually contained p63 positive myoepithelial
cells, and we demonstrated it is a useful marker for
highlighting these cells; and 3) malignant, p63 positive
cells were observed frequently in samples of DCIS and
IDC, although, based on careful cytomorphologic
evaluation, they may have been classiﬁed correctly as
malignant cells. Hence, based on previously published
data and on our ﬁndings, we advocate that anti-p63
antibodies may be used to identify myoepithelial cells
as well as to overcome the cytomorphologic distortion
of myoepithelial cells in FNABs of the breast. How-
ever, by no means may the evaluation of p63 staining
preclude a careful search for classic cytopathologic
criteria to rule in or rule out a diagnosis of malignancy.
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